Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072631 · ClinicalTrials.gov registry record · Phase 2
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 study of Advanced Non-Small-Cell Lung Cancer and Failed Prior Chemotherapy, sponsored by OSI Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT00072631 is a Phase 2 study of Advanced Non-Small-Cell Lung Cancer and Failed Prior Chemotherapy that has completed, run by OSI Pharmaceuticals. The registered enrollment target is 43 participants, below the 381-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00072631, a Phase 2 study of Advanced Non-Small-Cell Lung Cancer and Failed Prior Chemotherapy, has completed, sponsored by OSI Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.
Conditions Studied
Interventions
- DRUG Tarceva (Trademark) (erlotinib HCl, OSI-774)
Study Locations (1)
Texas
- Institute for Drug Development Cancer Therapy and Research Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2003-11-05 |
| Est. Completion | 2007-03-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072631
The ClinicalTrials.gov registry entry for NCT00072631 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 381-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target (89% lower). The listed sponsor is OSI Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tarceva (Trademark) (erlotinib HCl, OSI-774) is the first listed.
NCT00072631 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00072631 about?
NCT00072631 is a clinical study titled "Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer". The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.
What is the current status of trial NCT00072631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2003-11-05. Estimated completion is 2007-03-14.
What conditions does trial NCT00072631 study?
This clinical trial studies the following conditions: Advanced Non-Small-Cell Lung Cancer, Failed Prior Chemotherapy.
What interventions are being tested in trial NCT00072631?
The interventions under investigation include: Tarceva (Trademark) (erlotinib HCl, OSI-774) (DRUG).
Who is sponsoring clinical trial NCT00072631?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00072631 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Non-Small-Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
RECRUITING · Phase 2
-
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 2
-
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.